Xanamem™ identified as a good candidate to investigate for the treatment of Alzheimer’s disease – Phase I data published in the British Journal of Pharmacology
The research paper, Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™) has been published in the British Journal of Pharmacology (BJP). Highlights The research paper, which was co-authored by Alan Boyd, reports that Phase I results show Xanamem™ is safe and well tolerated with no major safety issues. The […]
